Canagliflozin (Invokana; Janssen) improves renal outcomes in patients with type 2 diabetes (T2D) with or at high risk for cardiovascular (CV) disease, according to new data from the CANVAS Program. The renal protective benefit was seen in patients with both reduced (eGFR <60mL/min/1.73m2) and preserved (eGFR ≥60mL/min/1.73m2) renal function.
In the analysis, treatment with canagliflozin decreased urinary albumin to creatinine ratio (UACR) from baseline eGFR by 17% in patients with preserved renal function and by 23% in patients with reduced eGFR (P =.01). In addition, canagliflozin resulted in a relative risk reduction of the composite endpoint (defined as 40% decline in eGFR, end-stage kidney disease or renal death) by 47% (hazard ratio [HR] 0.53; 95% CI, 0.39-0.73; P =.28) in patients with preserved eGFR and by 24% (HR 0.76; 95% CI, 0.49-1.17; P =.28) in patients with reduced eGFR. Findings were similar when the renal composite included doubling of serum creatinine instead of 40% decline in eGFR.
Moreover, among the 2 cohorts, no difference in risk of serious adverse events was observed and no new adverse events were reported beyond those previously reported from the CANVAS Program.
Invokana, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, is currently approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is supplied as 100mg and 300mg strength tablets.
For more information call (800) 526-7736 or visit Invokana.com.
This article originally appeared on MPR